Efficacy of peginterferon alpha-2a and ribavirin combination therapy in treatment-naive Estonian patients with chronic Hepatitis C

Central European Journal of Public Health

Volumn 20, Issue 2, 2012, Pages 150-155

  Brjalin, Vadim ^a,b   Salupere, Riina ^b   Tallo, Tatjana ^c,d   Kuznetsova, Tatiana ^c   Priimägi, Ljudmilla ^c   Tefanova, Valentina ^c  

^a WEST TALLINN CENTRAL HOSPITAL   (Estonia)

^b UNIVERSITY OF TARTU   (Estonia)

^c NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

^d Swedish Institute for Communicable Disease Control   (Sweden)

Author keywords

Chronic hepatitis C; Genotypes; Pegylated interferon; Ribavirin; Sustained virologic response; Viral load

Indexed keywords

EID: 84864272789     PISSN: 12107778     EISSN: None     Source Type: Journal    
DOI: 10.21101/cejph.a3706     Document Type: Article

References (48)

1. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007 May 7;13(17):2436-41.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005 Sep;5(9):558-67.
3. Baldo V, Baldovin T, Trivello R, Floreani A. Epidemiology of HCV infection. Curr Pharm Des. 2008; 14(17): 1646-54.
4. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol. 2008 Jan;48(1):148-62.
5. Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Sie-bert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health. 2009 Jan 22;9:34.
6. Tefanova V, Tallo T, Kutsar K, Priimgi L. Urgent action needed to stop spread of hepatitis B and C in Estonian drug users. Euro Surveill. 2006 Jan26;ll(1):E060126.3.
7. Priimägi L, Tefanova V, Tallo T. Emerging viral hepatitis B and C in Estonia. In: Berencsi G, Khan AS, Haloužka J, editors. Emerging biological threat. Amsterdam: IOS Press; 2005. p. 20-5.
8. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009 Apr;49(4): 1335-74.
9. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 - June 10-12,2002. Hepatology. 2002 Nov;36(5 Suppl l):S3-20.
10. Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008 Sep;135(3):821-9.
11. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology. 2003 Mar;37(3):600-9.
12. Hoofnagle JH, Wahed AS, Brown RS Jr, Howell CD, Belle SH; Virahep-C Study Group. Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. J Infect Dis. 2009 Apr 15;199(8):1112-20.
13. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005 Oct;42(4):962-73.
14. Smith DB, Simmonds P. Review: molecular epidemiology of hepatitis C virus. J Gastroenterol Hepatol. 1997 Jul;12(7):522-7.
15. Tallo T, Norder H, Tefanova V, Krispin T, Schmidt J, Ilmoja M, et al. Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominating subtype with time. J Med Virol. 2007 Apr;79(4):374-82.
16. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975-82.
17. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med. 2004 Mar 2; 140(5):370-81.
18. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005 Aug 18;436(7053):967-72.
19. Jacobson IM, Davis GL, El-Serag H, Negro F, Trtpo C. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2010 Nov;8(11):924-33; quiz el 17.
20. Almasio PL, Cottone C, D'Angelo F. Pegylated interferon therapy in chronic hepatitis C: lights and shadows of an innovative treatment. Dig Liver Dis. 2007 Sep;39 Suppl 1:S88-95.
21. Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, et al. Virological response in patients with hepatitis C virus genotype 1 b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig. 2008;28(1):9-16.
22. Erratum in: Clin Drug Investig. 2008;28(4):210.
23. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004 Apr;39(4):l 147-71. Erratum in: Hepatology. 2004 Jul;40(1):269.
24. Foster GR, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K, Wei-land O. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin. Scand J Gastroenterol. 2007 Feb;42(2):247-55.
25. Saludes V, Bracho MA, Valero O, Ardevol M, Planas R, Gonzalez-Candelas F, et al. Baseline prediction of combination therapy outcome in hepatitis C virus lb infected patients by discriminant analysis using viral and host factors. PLoS One. 2010 Nov 30;5(11):el4132.
26. Hofmann WP, Zeuzem S, Sarrazin C. Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy. J Clin Virol. 2005 Feb;32(2):86-91.
27. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al.; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intem Med. 2004 Mar2;140(5):346-55.
28. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005 Aug; 129(2):522-7.
29. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al.; ACCELERATE Investigators. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007 Jul 12;357(2): 124-34.
30. Francois C, Castelain S, Duverlie G, Capron D, Nguyen-Khac E. Optimizing the treatment of chronic viral hepatitis C. Expert Rev Gastroenterol Hepatol. 2009 Dec;3(6):607-13.
31. Dalgard O, Bjoro K, Ring-Larsen H, Verbaan H. In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials. Eur J Gastroenterol Hepatol. 2010 May;22(5):552-6.
32. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001 Sep 22;358(9286):958-65.
33. Lindh M, Alestig E, Arnholm B, Eilard A, Hellstrand K, Lagging M, et al. Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection. J Clin Microbiol. 2007Aug;45(8):2439-45.
34. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid viro-logical response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol. 2007 Jun;22(6):832-6.
35. Navaneethan U, Kemmer N, Neff G W. Predicting the probable outcome of treatment in HCV patients. Therap Adv Gastroenterol. 2009 Sep;2(5):287-302.
36. Fargion S, Fracanzani AL, Valenti L. Treatment choices for people infected with HCV. J Antimicrob Chemother. 2004 May;53(5):708-12.
37. Yuan HJ, Lee WM. Nonresponse to treatment for hepatitis C: current management strategies. Drugs. 2008;68(1):27-42.
38. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S 145-51.
39. Mihm U, Herrmann E, Sarrazin C, Zeuzem S. Review article: predicting response in hepatitis C virus therapy. Aliment Pharmacol Then 2006 Apr 15;23(8): 1043-54.
40. Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology. 2002 Nov;36(5 Suppl 1):S 185-94.
41. Everson GT, Hoefs JC, SeeffLB, Bonkovsky HL, Naishadham D, Shiffman ML, et al.; HALT-C Trial Group. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology. 2006 Dec;44(6): 1675-84.
42. Ferenci P. Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis. 2004;24 Suppl 2:25-31.
43. Narciso-Schiavon JL, Schiavon Lde L, Carvalho-Filho RJ, Sampaio JP, Batah PN, Barbosa DV, et al. Gender influence on treatment of chronic hepatitis C genotype 1. Rev Soc Bras Med Trop. 2010 May-Jun;43(3):217-23.
44. Reddy KR, Messinger D, Popescu M, Hadziyannis SJ. Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J Viral Hepat. 2009 Oct;16(10):724-31.
45. McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care. 2005 Oct;l 1(10 Suppl):S286-95; quiz S307-11.
46. Kuboki M, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, et al. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. J Gastroenterol Hepatol. 2007 May;22(5):645-52.
47. Erratum in: J Gastroenterol Hepatol. 2007 May;22(5):768.
48. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002 Nov;36(5 Suppl l):S237-44.